5858 HORTON STREET #455, EMERYVILLE, CA
Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
Annual Report to Security Holders
Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics Issues Pre-Funded Warrants for Common Stock
4D Molecular Therapeutics Reports $514 Million in Cash Position
Other Events
Kristian Humer Appointed CFO of 4D Molecular Therapeutics, Inc.
Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Q1
FY 2025
Q3
Q2
FY 2023
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement